Volkow Nora D, Li Ting-Kai
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA.
Pharmacol Ther. 2005 Oct;108(1):3-17. doi: 10.1016/j.pharmthera.2005.06.021.
Recent advances in the fields of genetics, molecular biology, behavioral neuropharmacology, and brain imaging have dramatically changed our understanding of the addictive process and why relapse occurs even in the face of catastrophic consequences. Addiction is now recognized as a chronic brain disease that involves complex interactions between repeated exposure to drugs, biological (i.e., genetic and developmental), and environmental (i.e., drug availability, social, and economic variables) factors. Its treatment, therefore, requires, in general, not only a long-term intervention but also a multipronged approach that addresses the psychiatric, medical, legal, and social consequences of addiction. Also, because addiction usually starts in adolescence or early adulthood and is frequently comorbid with mental illness, we need to expand our treatment interventions in this age group both for substance abuse and psychiatric disorders.
遗传学、分子生物学、行为神经药理学和脑成像领域的最新进展极大地改变了我们对成瘾过程的理解,以及为何即使面对灾难性后果仍会复发的原因。成瘾现在被认为是一种慢性脑部疾病,涉及反复接触毒品、生物因素(即遗传和发育因素)以及环境因素(即毒品可获得性、社会和经济变量)之间的复杂相互作用。因此,成瘾的治疗总体上不仅需要长期干预,还需要一种多管齐下的方法,以解决成瘾带来的精神、医学、法律和社会后果。此外,由于成瘾通常始于青春期或成年早期,且经常与精神疾病并发,我们需要针对这一年龄段的药物滥用和精神疾病扩大治疗干预措施。